topamax and glp 1 Semaglutide​ For Weight Loss TrimRX | Navigating Weight Loss:

The GLP-1 analogue market is a pharmaceutical phenomenon, projected to surge from $45.3 billion in 2025 to a staggering $122.3 billion by 2030

For example, Zepbound (tirzepatide) is a weight loss injection made by Eli Lilly

10.1093/ckj/sfac274 [DOI] [PMC free article] [PubMed] [Google Scholar] 29

A limitation of these published studies is the failure to consider the impact of glycosylation, which could shield some of the selected epitopes

While GLP-1 jabs have been shown in randomised controlled trials lead to weight loss of 15 to 20%, around half of all patients discontinue their use within the first year, with three-quarters stopping after two years